Seattle genetics, takeda announce additional analyses of adcetris echelon-1, echelon-2 phase 3 clinical trials

Seattle genetics and takeda announce additional analyses of adcetris® (brentuximab vedotin) echelon-1 and echelon-2 phase 3 clinical trials at the 2019 ash annual meeting.seattle genetics inc - four-year data continue to show superior progression-free survival of adcetris in combination with avd.seattle genetics inc - study analyses shows 31 percent reduction in risk of progression or death.
SGEN Ratings Summary
SGEN Quant Ranking